KEY CONCEPTS ON KETAMINE

Evidence-Based Treatments for:

Fatigue
Obsessive Compulsive Disorder
Chronic Pain
Anorexia Nervosa
Alcohol Use Disorder
Cocaine Use Disorder
Opioid Use Disorder
Amphetamine Use Disorder

Major Depressive Disorder
Bipolar Depression
Post Partum Depression
Post Traumatic Stress Disorder
Suicidal Thoughts
General Anxiety
Fibromyalgia
Social Anxiety

772.584.3692

Ketamine has been around since the early 1960’s and is well-known to help treat several psychiatric ailments. Scientific evidence suggests that Ketamine promotes synaptogenesis (new neuronal connections) and fosters neuronal growth via complex mechanisms.

The purpose of the PUR Ketamine Treatment Protocol is to enhance the state of the brain and improve mood and energy, thus making it easier to learn new information, and coping strategies, gain insight, and establish new behaviors and fresh patterns of thought. This is essential in the treatment of mental health disorders and substance use disorders. The use of ketamine to foster sobriety in substance use disorders is a novel concept that has been producing significantly better outcomes in recovery.

However, it is crucial for clients to actively engage in therapy and learning during the PUR Ketamine Treatment Protocol, as ketamine serves as a catalyst for recovery, yet requires the individual to engage in the supportive and structured treatment process. By combining the therapeutic benefits of ketamine with active participation in our program, individuals can optimize their potential for personal growth and achieve long-lasting positive changes in their lives.

FACTS ON KETAMINE
TREATMENT

Oral ketamine is a promising treatment option for individuals struggling with psychiatric ailments and substance abuse and may provide clients with the additional help they may need to maintain their sobriety and start living the full and productive life they deserve.

Post Ketamine Treatment:
• Results from this study demonstrate that the Ketamine procedure yielded stable remission in a large proportion of the alcohol-dependent population studied.
• 69.8% remained abstinent with Ketamine-assisted contra-attribution therapy while 24% remained abstinent in the control group.
• Chronic alcohol abuse remained abstinent with Ketamine assisted Therapy while 24% remained abstinent in the control group.
• Follow-up data collected two- and three-years post-ketamine treatment showed 40.7% abstinence after 2 years and 33.3% abstinence after 3 years.
Post Ketamine Treatment:
• 58% reduction in cravings using a normed craving scale VAR.
• 48% remained abstinent at 6 months compared with 0% in the control group.
• Another study, 48% remained abstinence after treatment compared with 11% of control group.
• Significant reductions in use following 1st dose, dissipates after 2 weeks.
• Rate of use reduced by 66% after first dose.
Post Ketamine Treatment:
• Abstinence rates at 1 month for higher dose Ketamine 85% compared to 55% at lose dose Ketamine.
• Cravings were notably decreased in the higher dose Ketamine treatment using the VAR scale.
• 50% of people receiving multiple-dose Ketamine VS single dose Ketamine were abstinent at 1-year follow-up VS 22% after a single dose.
• This study also concluded Ketamine treatment is helpful in long-term abstinence.
• Given the significant mortality associated with opioid overdose, the potential of ketamine to address opioid use disorders is particularly encouraging.
• A CDC study shows that 1 out of 9 women in the United States experience symptoms of postpartum depression.
• Published in the Journal of Medicine and Life, clinical trial conducted on women undergoing scheduled caesarian concluded that a single dose of ketamine significantly decreases the rate of developing postpartum depression.
• Studies found Ketamine treatment is effective for 70% of patients with PDD compared to antidepressant medications, which works for about 40% of patients.
• Published in July of 2022, Wolfson et al. found low concentrations of ketamine and metabolites in breast milk with a rapid decline in concentration within several hours post-dosing.
• It is generally considered safe to resume regular breastfeeding third-day post-treatment.
• Multiple low doses of sublingual ketamine improved mood level and stability in 77% of patients.
• Studies have shown that a single dose of ketamine was able to rapidly reduce suicidal thoughts within 1 day with bipolar disorder patients.
• Studies have shown that 48.1% patients with Bipolar Depression showed a response to Ketamine treatment within 1 week.
• Multiple low doses sublingual Ketamine improved sleep in 77% of patients.
• Multiple low doses of sublingual Ketamine improved cognition in 77% of patients.
• Ketamine functions as an N-methyl-D-aspartate (NMDA) receptor antagonist, which blocks the activity of NMDA receptors in the brain. This mechanism of action is thought to play a role in its potential therapeutic effects for anorexia.
• Ketamine may help alleviate symptoms associated with anorexia by modulating neural circuits involved in reward processing, emotion regulation, and body image perception.
• Case reports described improvements in eating disorder symptoms following ketamine infusions, and a small study found reduced depressive and anxiety symptoms, as well as improvements in body image concerns with ketamine treatment.